keyword
https://read.qxmd.com/read/38519381/pain-is-what-hurts-an-exploration-of-perception-and-management-of-pain-in-peripheral-blood-stem-cell-donors
#1
JOURNAL ARTICLE
Suzanna M van Walraven, Leon C Witte, Femmeke Prinsze, Johanna C Wiersum-Osselton, Ivan Bank
BACKGROUND: Pain is a side effect of Granulocyte-Colony Stimulating Factor (G-CSF) administration. This prospective study investigates various aspects including pain perception occurring in Peripheral Blood Stem Cell (PBSC) donors. MATERIALS AND METHODS: Related and unrelated PBSC donors were prospectively studied. Donors recorded pain symptoms during the four-day period of G-CSF administration using the McGill Pain Questionnaire, a Visual Analog Scale and a pain diary...
March 19, 2024: Transfusion and Apheresis Science
https://read.qxmd.com/read/38462734/a-global-assessment-of-hemostatic-function-of-healthy-allogeneic-stem-cell-donors-undergoing-apheresis-by-rotational-thromboelastometry
#2
JOURNAL ARTICLE
Neslihan Cilek, Elif Ugurel, Ozgur Can Eren, Ozlem Yalcin, Olga Meltem Akay
INTRODUCTION: Peripheral blood stem cell (PBSC) collection via apheresis requires the administration of granulocyte colony-stimulating factor (filgrastim) to stem cell donors. Several reports have shown that filgrastim administration and apheresis procedure induce a hypercoagulable state across PBSC collection, which might predispose certain donors to thrombotic complications. METHODS: We evaluated the hemostatic functions of healthy allogeneic stem cell donors by rotational thromboelastometry (ROTEM)...
March 10, 2024: Therapeutic Apheresis and Dialysis
https://read.qxmd.com/read/38454131/long-term-follow-up-of-cancer-and-catastrophic-diseases-in-hematopoietic-stem-cell-donors-a-comprehensive-matched-cohort-study
#3
JOURNAL ARTICLE
Sung-Chao Chu, Chia-Jung Hsieh, Chi-Cheng Li, Shang-Hsien Yang, Szu-Chin Li, Woei-Yau Kao, Dian-Kun Li, Yi-Feng Wu, Ruey-Ho Kao, Kuo-Liang Yang, Tso-Fu Wang
Hematopoietic stem cell (HSC) transplantation, using either bone marrow (BM) or peripheral blood stem cells (PBSC), is a well-established therapy for various hematologic and non-hematologic diseases. However, the long-term health outcomes after HSC donation remain a major concern for several potential donors. Thus, we aimed to conduct a matched cohort study of 5003 unrelated donors (1099 BM and 3904 PBSC) and randomly selected 50,030 matched controls based on age, sex, and resident area from the donor registry between 1998 and 2018...
March 7, 2024: Bone Marrow Transplantation
https://read.qxmd.com/read/38436082/co-transplantation-of-umbilical-cord-mesenchymal-stem-cells-and-peripheral-blood-stem-cells-in-children-and-adolescents-with-refractory-or-relapsed-severe-aplastic-anemia
#4
JOURNAL ARTICLE
Fangfang Yuan, Minghui Li, Xudong Wei, Yuewen Fu
To evaluate the co-transplantation efficacy of umbilical cord mesenchymal stem cells (UC-MSCs) and peripheral blood stem cells (PBSCs) as a novel approach for refractory or relapsed severe aplastic anemia (R/R SAA) in children and adolescents, thirty-two children and adolescents diagnosed with R/R SAA underwent a retrospective chart review. The patients were categorized into two groups based on the source of PBSCs: the matched sibling donor (MSD) group and the unrelated donor (UD) group. No adverse events related to UC-MSC infusion occurred in any of the patients...
March 4, 2024: Pediatric Hematology and Oncology
https://read.qxmd.com/read/38410106/case-report-pulse-cyclophosphamide-for-treatment-of-multi-agent-refractory-hepatic-graft-versus-host-disease
#5
Yijun Cai, Amir Ali, Elan Filler, Rua Bayati, Tanjia Toma, Omar Zaki, George Yaghmour, Abdullah Ladha, Karrune Woan, Eric Tam, Preet M Chaudhary
Graft-versus-host disease (GVHD) is a common complication in patients receiving allogeneic hematopoietic stem cell transplantation (HSCT). GVHD is characterized as either acute or chronic based on symptomatology and histopathological findings. Despite advancements in disease-targeting therapeutics, steroid-refractory GVHD remains a significant contributor to mortality in HSCT recipients, highlighting the gaps in our understanding of its pathophysiology and treatment strategies. We present the case of a 46-year-old woman diagnosed with acute undifferentiated leukemia, who exhibited persistently elevated levels of serum total bilirubin (T...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38387943/-research-progress-on-the-application-strategies-of-plerixafor-in-the-peripheral-blood-stem-cell-mobilization-for-autologous-transplantation-review
#6
JOURNAL ARTICLE
Ying Fang, Pei-Pei Ye
Plerixafor, an analog of C-X-C motif chemokine receptor 4 (CXCR4), which allows the release of stem cells from the bone marrow into peripheral blood (PB) by disrupting the interaction of CXCR4 with stromal cell-derived factor-1 (SDF-1), is effective in mobilization for peripheral blood stem cells (PBSC). Due to its market approval has not been long and its high price in China, the clinical application of plerixafor is still very limited. The clinicians are actively seeking the optimal use of plerixafor to improve the success rate of PBSC collection and reduce the cost...
February 2024: Zhongguo Shi Yan Xue Ye Xue za Zhi
https://read.qxmd.com/read/38374026/post-transplant-cyclophosphamide-versus-anti-thymocyte-globulin-after-reduced-intensity-peripheral-blood-allogeneic-cell-transplantation-in-recipients-of-matched-sibling-or-10-10-hla-matched-unrelated-donors-final-analysis-of-a-randomized-open-label-multicenter
#7
RANDOMIZED CONTROLLED TRIAL
Eolia Brissot, Myriam Labopin, Helene Labussière, Gaelle Fossard, Patrice Chevallier, Thierry Guillaume, Ibrahim Yakoub-Agha, Micha Srour, Claude-Eric Bulabois, Anne Huynh, Sylvain Chantepie, Anne-Lise Menard, Marie-Therese Rubio, Patrice Ceballos, Rémy Dulery, Sabine Furst, Florent Malard, Didier Blaise, Mohamad Mohty
The use of post-transplantation cyclophosphamide (PTCy) for graft-versus-host disease (GVHD) prophylaxis is not established after reduced intensity conditioning (RIC) hematopoietic stem cell transplantation (HSCT) from fully matched donors. This was a randomized, open-label, multicenter, phase 2 trial. All patients received a RIC regimen with fludarabine, intravenous busulfan for 2 days (Flu-Bu2), and a peripheral blood stem cell (PBSC) graft from a matched related or 10/10 HLA-matched unrelated donor. Patients were randomly assigned to receive anti-thymocyte globulin (ATG) 5 mg/kg plus standard GVHD prophylaxis or PTCy 50 mg/kg/d at days +3 and +4 plus standard GVHD prophylaxis...
February 19, 2024: Blood Cancer Journal
https://read.qxmd.com/read/38330190/differential-clinical-impact-of-letermovir-prophylaxis-according-to-graft-sources-a-ksgct-multicenter-retrospective-analysis
#8
JOURNAL ARTICLE
Takashi Toya, Kota Mizuno, Masatoshi Sakurai, Jun Kato, Takehiko Mori, Noriko Doki, Shinichi Masuda, Nobuyuki Aotsuka, Shokichi Tsukamoto, Emiko Sakaida, Yuki Nakajima, Shin Fujisawa, Shinichiro Machida, Yasuyuki Aoyama, Hiroki Yokoyama, Katsuhiro Shono, Yoshihiro Hatta, Kensuke Usuki, Keisuke Kataoka, Yoshinobu Kanda
Clinically significant cytomegalovirus infection (csCMVi) is frequently observed after allogeneic hematopoietic stem cell transplantation (HSCT) and prophylaxis with letermovir is commonly adopted. However, the clinical benefit of letermovir prophylaxis according to graft sources has not been sufficiently elucidated. We retrospectively analyzed 2,194 CMV-seropositive HSCT recipients (236 with letermovir prophylaxis and 1,958 without prophylaxis against CMV). csCMVi was significantly less frequent in patients with than in those without letermovir prophylaxis (23...
December 15, 2023: Blood Advances
https://read.qxmd.com/read/38317015/dual-t-cell-depletion-for-graft-versus-host-disease-prevention-in-peripheral-blood-haploidentical-hematopoietic-cell-transplantation-for-adults-with-hematological-malignancies
#9
JOURNAL ARTICLE
Tommy Alfaro Moya, Maria Queralt Salas, Abel Santos Carreira, Eshetu G Atenafu, Arjun Datt Law, Wilson Lam, Ivan Pasic, Dennis Dong Hwan Kim, Fotios V Michelis, Igor Novitzky Basso, Armin Gerbitz, Jeffrey Howard Lipton, Rajat Kumar, Jonas Mattsson, Auro Viswabandya
The ideal immunosuppressive agents to complement post-transplant cyclophosphamide (PTCy) in PBSC-based haploidentical hematopoietic cell transplantation (haplo-HCT) remain debated. This study looks at our experience with ATG-PTCy-Cyclosporine (CsA) prophylaxis in PB haplo-HCT since 2015. Between October 2015 and December 2021, 157 adults underwent haploidentical hematopoietic cell transplantation (haplo-HCT) using a GVHD prophylaxis regimen comprising rabbit-ATG, PTCy, and CsA. Among these patients, 76.4% received a total ATG dose of 4...
February 5, 2024: Bone Marrow Transplantation
https://read.qxmd.com/read/38267561/efficacy-of-prophylactic-antibiotics-for-the-prevention-of-neutropenic-fever-in-patients-with-multiple-myeloma-receiving-high-dose-cyclophosphamide-for-stem-cell-mobilization
#10
JOURNAL ARTICLE
Li-Qiong Hou, Jun-Ru Liu, Jing-Li Gu, Mei-Lan Chen, Li-Fen Kuang, Bei-Hui Huang, Wai-Yi Zou, Juan Li
High-dose cyclophosphamide (HD-Cy) (3 g/m2 ) plus granulocyte colony-stimulating factor (G-CSF) is a very effective regimen for peripheral blood stem cell (PBSC) mobilization. Unfortunately, it is associated with an increased risk of neutropenic fever (NF). We analyzed the effect of NF on PBSC apheresis results and the efficacy of prophylactic antibiotics for the prevention of NF associated with HD-Cy plus G-CSF for PBSC mobilization in patients with newly diagnosed multiple myeloma (MM). First, patients were divided into NF ( +) and NF ( -) groups according to whether they suffered from NF during mobilization...
January 25, 2024: Annals of Hematology
https://read.qxmd.com/read/38223487/haploidentical-transplant-with-post-transplant-cyclophosphamide-for-acute-myeloid-leukaemia-and-myelodysplastic-syndromes-patients-the-role-of-previous-lines-of-therapy
#11
JOURNAL ARTICLE
Daniele Avenoso, Fabio Serpenti, Liron Barnea Slonim, Styliani Bouziana, Francesco Dazzi, Guy Hannah, Michelle Kenyon, Varun Mehra, Austin Kulasekararaj, Pramila Krishamurthy, Mili Naresh Shah, Sharon Lionel, Antonio Pagliuca, Victoria Potter
BACKGROUND: Allogeneic haematopoietic stem-cell transplant is an option, potentially curative, for high-risk acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) patients. Post-transplant cyclophosphamide administration allows for the selection of haploidentical donors in patients who are eligible for the procedure but do not have a fully matched donor since it can overcome the HLA barrier. There is still an active debate on whether intensifying the conditioning regimen is necessary with haploidentical donors when peripheral blood stem cells are used as the graft source...
2024: Mediterranean Journal of Hematology and Infectious Diseases
https://read.qxmd.com/read/38186371/safety-and-efficacy-of-peripheral-blood-stem-cells-collection-in-healthy-children-and-pediatric-patients-with-thalassemia-major-weighing-20%C3%A2-kg-or-less
#12
JOURNAL ARTICLE
Libai Chen, Jianyun Wen, Xiaoxiao Xu, Jing Du, Yongsheng Ruan, Xiaoqin Feng, Juan Li, Yuelin He, Xuedong Wu
BACKGROUND: Peripheral blood stem cell (PBSC) collection in children poses challenges due to their small size, low body weight (BW), and unique pediatric physiology, especially among children weighing 20 kg (kg) or less. METHODS: PBSC collection data of both healthy children and patients with thalassemia major (TM) weighing 20 kg or less between January 2013 and December 2020 were reviewed. Moreover, PBSCs characteristics along with various aspects of efficiency and safety between healthy donors and patients with TM were compared...
January 8, 2024: Journal of Clinical Apheresis
https://read.qxmd.com/read/38184211/recruiting-refugees-and-migrants-as-potential-hematopoietic-stem-cell-donors-to-serve-patients-of-comparable-ethnicities-with-rare-human-leucocyte-antigen-patterns-the-blustar-nrw-project-in-north-western-germany
#13
JOURNAL ARTICLE
F M Heinemann, C Baumgart, C Binder, V Börger, J C Fischer, A Heinold, C Jiménez Klingberg, V Lenz, S Riebschläger, T Zeiler, P A Horn, L Kordelas
Currently, approximately 19 million people with a migration background live in Germany. The majority of those descend from regions where the population has a genetically different distribution of HLA antigens when compared to the HLA frequencies usually found in North Western Europe. In case of severe haematological disorders of these individuals, allogeneic stem cell transplantation may be the treatment of choice. However, finding appropriate histocompatible hematopoietic stem cell donors continues to be a major challenge...
January 4, 2024: Transplant Immunology
https://read.qxmd.com/read/38167085/identifying-optimal-candidates-for-autologous-peripheral-blood-stem-cell-therapy-in-patients-with-decompensated-liver-cirrhosis-a-prognostic-scoring-system
#14
JOURNAL ARTICLE
Siyuan Tian, Guanya Guo, Xia Zhou, Yansheng Liu, Gui Jia, Linhua Zheng, Lina Cui, Kemei Wang, Miao Zhang, Keshuai Sun, Shuoyi Ma, Chunmei Yang, Xinmin Zhou, Changcun Guo, Yulong Shang, Ying Han
BACKGROUND: Stem cell transplantation shows great potential to improve the long-term survival of cirrhosis patients. However, therapeutic effects may not be homogeneous across the whole study population. This study constructed an easy-to-use nomogram to improve prognostic prediction and aid in treatment decision making for cirrhotic patients. METHODS: From August 2005 to April 2019, 315 patients with decompensated cirrhosis receiving autologous peripheral blood stem cell (PBSC) transplantation were enrolled in this study...
January 2, 2024: Stem Cell Research & Therapy
https://read.qxmd.com/read/38161351/persistence-of-dengue-genome-in-a-remotely-infected-patient
#15
Soraya Thaivanich, Jirayu Visuthranukul, Kesinee Arunyingmongkol, Udomsak Bunworasate, Padet Siriyasatien, Wanla Kulwichit
BACKGROUND: Dengue virus infection is an intriguing illness. It is traditionally thought of as a self-limited and nonpersistent disease. OBJECTIVES: We report a case with persistent dengue virus genome detectable in hematopoietic cells of a person with remote infection. METHODS: A patient with multiple myeloma in remission was prepared for peripheral blood stem cell (PBSC) transplantation. Plasma and G-CSF-stimulated, mobilized PBSCs were collected...
December 2023: Asian Biomedicine: Research, Reviews and News
https://read.qxmd.com/read/38155507/effective-peripheral-blood-stem-cell-collection-in-a-4-6-kg-child
#16
Jennifer M Jones, Joseph E Kiss, Irina Chibisov, Paulina Horvei, Heather Stanczak, Carol Burda, Wei Clark, Joan Sevcik, Carolyn Kilonsky, Alesia Kaplan
BACKGROUND: Due to unique technical challenges, effective peripheral blood stem cell collections (PBSCs) have not been consistently reported in patients weighing less than 5 kg. We describe three PBSCs performed in a 4.6-kg child undergoing myeloablative chemotherapy for high-grade glioma. STUDY DESIGN AND METHODS: A multidisciplinary group representing the clinical and apheresis teams adapted a PBSC protocol to accommodate the patient's size and collection targets...
December 28, 2023: Transfusion
https://read.qxmd.com/read/38147484/the-impact-of-cryoprotectant-exposure-time-on-post-thaw-viability-of-autologous-and-allogeneic-hematopoietic-stem-cells-and-leukocyte-subpopulations
#17
JOURNAL ARTICLE
Vladimira Rimac, Ines Bojanić, Sanja Dabelić, Branka Golubić Ćepulić
Although the use of cryoprotectant dimethyl sulfoxide (DMSO) is the gold standard in cryopreservation of hematopoietic stem cells, it is well known that it has a negative effect on cell viability. The aim of this prospective study was to examine how the length of post-thaw exposure to DMSO affects the cell viability and stability of peripheral blood stem cell (PBSC) samples. Additionally, the effects of donor type and pre-cryopreservation storage time on post-thaw viability during the stability study were evaluated...
December 1, 2023: Acta Pharmaceutica
https://read.qxmd.com/read/38146354/gvhd-relapse-free-survival-after-peripheral-blood-hematopoietic-cell-transplantation-for-hematologic-malignancies
#18
JOURNAL ARTICLE
Deepesh P Lad, Prashant Chhabra, Kripa Shanker Kasudhan, Shaweta Kaundal, Madhu Chopra, Charanpreet Singh, Aditya Jandial, Arihant Jain, Gaurav Prakash, Alka Khadwal, Pankaj Malhotra
The preferred choice for hematopoietic cell transplantation (HCT) donors in India is a matched related donor (MRD) followed by a haploidentical (haplo) donor for patients with hematological malignancies. International data in the haplo-HCT setting is mainly using bone marrow as a source. Almost all HCTs in India use peripheral blood stem cells (PBSC), which increases the risk of graft-versus-host disease (GVHD). In this single-center prospective study from 2017 to 2021, we sought to compare these outcomes prospectively in adult patients with hematological malignancies...
August 25, 2023: Blood Cell Ther
https://read.qxmd.com/read/38103787/alemtuzumab-dual-graft-versus-host-disease-prophylaxis-and-lower-cd3-t-cell-doses-equalize-rates-of-acute-and-chronic-graft-versus-host-disease-in-pediatric-patients-receiving-allogeneic-hematopoietic-stem-cell-transplantation-with-matched-unrelated-donor-peripheral
#19
MULTICENTER STUDY
Su Han Lum, Beki James, Giorgio Ottaviano, Anna-Maria Ewins, Katharine Patrick, Salah Ali, Ben Carpenter, Juliana Silva, Sanjay Tewari, Caroline Furness, Arun Thomas, Geoff Shenton, Denise Bonney, John Moppett, Sophie Hambleton, Andrew R Gennery, Persis Amrolia, Brenda Gibson, Rachael Hough, Kanchan Rao, Mary Slatter, Robert Wynn
Data comparing hematopoietic stem cell transplantation (HSCT) using bone marrow (BM) or peripheral blood stem cell (PBSC) grafts in children after alemtuzumab-based conditioning are lacking. We investigated whether in vivo T cell depletion using alemtuzumab could reduce the risk of severe acute graft-versus-host disease (aGVHD) and chronic GVHD (cGVHD) after HSCT with matched unrelated donor (MUD) BM or PBSCs. This retrospective multicenter study included 397 children (BM group, n = 202; PBSC group, n = 195) who underwent first MUD HSCT at 9 pediatric centers in the United Kingdom between 2015 and 2019...
March 2024: Transplantation and cellular therapy
https://read.qxmd.com/read/38087402/osteochondral-regeneration-in-the-knee-joint-with-autologous-peripheral-blood-stem-cells-plus-hyaluronic-acid-after-arthroscopic-subchondral-drilling-report-of-five-cases
#20
Khay-Yong Saw, Adam W Anz, Caroline Siew-Yoke Jee, Soo-Fin Low, Amal Dawam, Alisha Ramlan
BACKGROUND: Treatment of osteochondral defects (OCDs) of the knee joint remains challenging. The purpose of this study was to evaluate the clinical and radiological results of osteochondral regeneration following intra-articular injections of autologous peripheral blood stem cells (PBSC) plus hyaluronic acid (HA) after arthroscopic subchondral drilling into OCDs of the knee joint. CASE PRESENTATION: Five patients with OCDs of the knee joint are presented. The etiology includes osteochondritis dissecans, traumatic knee injuries, previously failed cartilage repair procedures involving microfractures and OATS (osteochondral allograft transfer systems)...
December 12, 2023: Orthopaedic Surgery
keyword
keyword
161800
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.